

Clerk of the House of Representatives Legislative Resource Center B-106 Cannon Building Washington, DC 20515	Secretary of the Senate Office of Public Records 232 Hart Building Washington, DC 20510
---	--

SECRETARY OF THE SENATE

03 FEB 24 PM 4

LOBBYING REPORT

Lobbying Disclosure Act of 1995 (Section 5) - All Filers Are Required To Complete This Page

1. Registrant Name American Pharmaceutical Association			
2. Address <input type="checkbox"/> Check if different than previously reported 2215 Constitution Avenue, NW			
3. Principal Place of Business (if different from line 2) City: Washington State/Zip (or Country) DC 20037			
4. Contact Name	Telephone	E-mail (optional)	5. Senate ID #
Mary Singletary	(202) 429-7572	MSingletary@APhAnet.org	3017
7. Client Name <input checked="" type="checkbox"/> Self			6. House ID #
Self			3162

TYPE OF REPORT 8. Year 2002 Midyear (January 1-June 30) OR Year End (July 1-Dec 31)

9. Check if this filing amends a previously filed version of this report


10. Check if this is a Termination Report ⇨ Termination Date _____

11. No Lobbying

INCOME OR EXPENSES - Complete Either Line 12 OR Line 13

<p align="center">12. Lobbying Firms</p> <p>INCOME relating to lobbying activities for this reporting period was:</p> <p>Less than \$10,000 <input type="checkbox"/></p> <p>\$10,000 or more <input type="checkbox"/> ⇨ \$ _____ Income (nearest \$20,000)</p> <p>Provide a good faith estimate, rounded to the nearest \$20,000, of all lobbying related income from the client (including all payments to the registrant by any other entity for lobbying activities on behalf of the client).</p>	<p align="center">13. Organizations</p> <p>EXPENSES relating to lobbying activities for this reporting period were:</p> <p>Less than \$10,000 <input type="checkbox"/></p> <p>\$10,000 or more <input type="checkbox"/> ⇨ \$ <u>169,926.00</u> Expenses (nearest \$20,000)</p> <p>14. REPORTING METHOD. Check box to indicate accounting method. See instructions for description of method.</p> <p><input type="checkbox"/> Method A. Reporting amounts using LDA definition</p> <p><input type="checkbox"/> Method B. Reporting amounts under section 60 Internal Revenue Code</p> <p><input type="checkbox"/> Method C. Reporting amounts under section 162 Internal Revenue Code</p>
---	--

Signature _____



Printed Name and Title Mary Singleary, Administrative Coordinator

LD-2 (REV. 6/98)

Registrant Name American Pharmaceutical Association Client Name Self

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant is engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, information as requested. Attach additional page(s) as needed.

15. General issue area code HCR (one per page)

16. Specific lobbying issues

Conquering Pain Act of 2001 (H.R. 2156/S. 1024)
Medical Error Reporting and Medication Safety (H.R. 4889, S.2590, S.3029, and H.R. 5478)
Increasing Federal Support for the Indian Health Services and Tribal Health Care Programs - FY2003 Interior Appropriations
Standards for Privacy and Individually Identifiable Health Information (65 FR 82462-82829, 12/28/00), (67 FR 14775-14815, 3/27/02)
H.R. 3448/S. 1765: Bioterrorism Preparedness Act of 2001; Prescription Drug User Fee Re-Authorization

17. House(s) of Congress and Federal agencies contacted

Check if None

U.S. Senate
U.S. House of Representatives
Department of Health and Human Services
Drug Enforcement Administration

18. Name of each individual who acted as a lobbyist in this issue area

Name	Covered Official Position (if applicable)
Susan C. Winckler, RPh, JD	
Lisa M. Geiger	
Susan K. Bishop	
Mitch C. Rothholz	

19. Interest of each foreign entity in the specific issues listed on line 16 above

Check if None

Signature Mary Singletay Date 2/13/03

Registrant Name American Pharmaceutical Association Client Name Self

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant is engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, information as requested. Attach additional page(s) as needed.

15. General issue area code MMM (one per page)

16. Specific lobbying issues

Medicare Prescription Drug Benefit (S. 2625, H.R. 4954, H.R. 3626, H.R. 4741, S. 2729, S. 2736)
Payment for Services/Recognition of Pharmacists as Providers (S. 974, H.R. 2799)
Administration's Medicare-endorsed Prescription Drug Discount Card

17. House(s) of Congress and Federal agencies contacted

Check if None

U.S. Senate
U.S. House of Representatives
Department of Health and Human Services
White House

18. Name of each individual who acted as a lobbyist in this issue area

Name	Covered Official Position (if applicable)
Susan C, Winckler, RPh, JD	
Lisa M. Geiger	
Susan K. Bishop	

19. Interest of each foreign entity in the specific issues listed on line 16 above

Check if None

Signature Mary Singletay Date 2/13/03

Printed Name and Title Mary Singletay, Administrative Coordinator

Registrant Name American Pharmaceutical Association Client Name Self

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the re engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, information as requested. Attach additional page(s) as needed.

15. General issue area code PHA (one per page)

16. Specific lobbying issues

Pharmacy Education Aid Act of 2001 (H.R. 2173/S. 1806)
Implementation of Pharmacy Compounding Regulations (FDA Modernization Act of 1997)
H.R. 68/S. 1132. To amend the Federal Food, Drug, & Comestic Act re: distribution chain of prescription drugs
Dietary Supplement Health and Education Act
Electronic Transmission of Prescriptions
Medguide Implementation

17. House(s) of Congress and Federal agencies contacted Check if None

U.S. Senate
U.S. House of Representatives
Department of Health and Human Services
Drug Enforcement Adminstration
Food and Drug Administration

18. Name of each individual who acted as a lobbyist in this issue area

Name	Covered Official Position (if applicable)
Susan C, Winckler, RPh, JD	
Lisa M. Geiger	
Susan K. Bishop	

19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None

Signature *Mary Singleton* Date 2/13/03

Registrant Name American Pharmaceutical Association Client Name Self

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant is engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, information as requested. Attach additional page(s) as needed.

15. General issue area code PHA (one per page)

16. Specific lobbying issues

(continuation of PHA)

Management of High Risk Medications
Importation of Medications (S. 2244, H.R. 4614)
S. 1533 Healthcare Safety Net Amendments

17. House(s) of Congress and Federal agencies contacted

Check if None

U.S. Senate
U.S. House of Representatives
Department of Health and Human Services
Drug Enforcement Administration
Food and Drug Administration

18. Name of each individual who acted as a lobbyist in this issue area

Name	Covered Official Position (if applicable)
Susan C. Winckler, RPh, JD	
Lisa M. Geiger	
Susan K. Bishop	

19. Interest of each foreign entity in the specific issues listed on line 16 above

Check if None

Signature

Mary Singletary

Date

2/13/11

Registrant Name American Pharmaceutical Association Client Name Self

Information Update Page - Complete ONLY where registration information has changed.

20. Client new address

N/A

21. Client new principal place of business (if different from line 20)

City

State/Zip (or Country)

22. New general description of client's business or activities

LOBBYIST UPDATE

23. Name of each previously reported individual who is no longer expected to act as a lobbyist for the client

ISSUE UPDATE

24. General lobbying issues previously reported that no longer pertain

AFFILIATED ORGANIZATIONS

25. Add the following affiliated organization(s)

Name	Address	Principal Place of Bu- (city and state or co

26. Name of each previously reported organization that is no longer affiliated with the registrant or client

FOREIGN ENTITIES

27. Add the following foreign entities

Name	Address	Principal place of business (city and state or country)	Amount of contribution for lobbying activities

28. Name of each previously reported foreign entity that no longer owns, or controls, or is affiliated with the registrant affiliated organization

Signature

Mary Singleton

Date

2/13

Printed Name and Title Mary Singletary, Administrative Coordinator

Form LD-2 (Rev. 6/98)

Page